With potential $1.7 billion deal, Genentech kicks its cancer immunotherapy work into new gear
February 25, 2020 at 16:38 PM EST
The South San Francisco-based biotech giant will work in tandem with its new partner on bicyclic peptides that help the immune system attack cancer.
